Pushing the boundaries of SBRT in irradiated territories for nodal oligorecurrent prostate cancer: outcomes of the CYGNUS multicentric retrospective study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
150 patients relapsing on 192 nodal sites were retrospectively included, from 13 French centers.
I · Intervention 중재 / 시술
radical prostatectomy as primary treatment
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] The CYGNUS retrospective study suggests that reirradiation with SBRT for PNMOR is associated with a low rate of toxicity. However, further data with plan summation and longer follow-up are needed to confirm these findings.
[PURPOSE] the CYGNUS study aims to assess both toxicity and efficacy of stereotactic body radiotherapy (SBRT) performed as salvage approach for pelvic nodal metachronous oligorecurrent (PNMOR) hormone
- p-value p=0.004
- p-value p=0.006
- 95% CI 1.25-3.26
- HR 2.02
- 추적기간 30.5 months
APA
Anger E, Supiot S, et al. (2026). Pushing the boundaries of SBRT in irradiated territories for nodal oligorecurrent prostate cancer: outcomes of the CYGNUS multicentric retrospective study.. International journal of radiation oncology, biology, physics. https://doi.org/10.1016/j.ijrobp.2026.03.020
MLA
Anger E, et al.. "Pushing the boundaries of SBRT in irradiated territories for nodal oligorecurrent prostate cancer: outcomes of the CYGNUS multicentric retrospective study.." International journal of radiation oncology, biology, physics, 2026.
PMID
41864432 ↗
Abstract 한글 요약
[PURPOSE] the CYGNUS study aims to assess both toxicity and efficacy of stereotactic body radiotherapy (SBRT) performed as salvage approach for pelvic nodal metachronous oligorecurrent (PNMOR) hormone-sensitive prostate cancer (PCa), in previously irradiated territory.
[METHODS AND MATERIALS] Inclusion criteria were histologically history of proven PCa, locally treated with a radical intent and a biochemical relapse as defined by the European Association of Urology guidelines. All patients had a radiological suspicion of PNMOR, defined as a recurrence occurring in pelvic nodal areas with up to 5 suspect lymph nodes. Reirradiation was defined according to the ESTRO-EORTC consensus on re-irradiation as an irradiation with a geometrical overlap with a previous course of RT.
[RESULTS] A total of 155 re-irradiation among 150 patients relapsing on 192 nodal sites were retrospectively included, from 13 French centers. The majority of patients (80.7%) received radical prostatectomy as primary treatment. After a median follow-up of 30.5 months, late grade 2 and grade 3 GI and GU toxicity occurred in 1.9%, 0% and 7.1% and 2.6% of the cases, respectively. The 2-year radiological progression-free survival (rPFS) reached respectively 44.6% (95% CI: 36.2% - 55%).. The 2-year androgen deprivation therapy-free survival (ADT-FS) reached 52.6% (95% CI: 42% - 65.9%). Previous ADT prescription was predictive in multivariable analysis of both rPFS (HR:2.02, 95%CI: 1.25-3.26, p=0.004) and ADT-FS (HR:2.49, 95%CI: 1.28-4.72, p=0.006). A PSA doubling time <5months correlated with a shorter ADT-FS (AUC 0.629, p= 0.014).
[CONCLUSION] The CYGNUS retrospective study suggests that reirradiation with SBRT for PNMOR is associated with a low rate of toxicity. However, further data with plan summation and longer follow-up are needed to confirm these findings.
[METHODS AND MATERIALS] Inclusion criteria were histologically history of proven PCa, locally treated with a radical intent and a biochemical relapse as defined by the European Association of Urology guidelines. All patients had a radiological suspicion of PNMOR, defined as a recurrence occurring in pelvic nodal areas with up to 5 suspect lymph nodes. Reirradiation was defined according to the ESTRO-EORTC consensus on re-irradiation as an irradiation with a geometrical overlap with a previous course of RT.
[RESULTS] A total of 155 re-irradiation among 150 patients relapsing on 192 nodal sites were retrospectively included, from 13 French centers. The majority of patients (80.7%) received radical prostatectomy as primary treatment. After a median follow-up of 30.5 months, late grade 2 and grade 3 GI and GU toxicity occurred in 1.9%, 0% and 7.1% and 2.6% of the cases, respectively. The 2-year radiological progression-free survival (rPFS) reached respectively 44.6% (95% CI: 36.2% - 55%).. The 2-year androgen deprivation therapy-free survival (ADT-FS) reached 52.6% (95% CI: 42% - 65.9%). Previous ADT prescription was predictive in multivariable analysis of both rPFS (HR:2.02, 95%CI: 1.25-3.26, p=0.004) and ADT-FS (HR:2.49, 95%CI: 1.28-4.72, p=0.006). A PSA doubling time <5months correlated with a shorter ADT-FS (AUC 0.629, p= 0.014).
[CONCLUSION] The CYGNUS retrospective study suggests that reirradiation with SBRT for PNMOR is associated with a low rate of toxicity. However, further data with plan summation and longer follow-up are needed to confirm these findings.